Health / Medical Topics

    Efalizumab

    Pronunciation

    Definition 1

    A monoclonal antibody used to treat psoriasis (a chronic skin disease). It is also being studied in the treatment of graft-versus-host disease (GVHD) of the skin after a donor stem cell transplant. Efalizumab binds to a molecule called LFA-1, and blocks the action of T cells (a type of white blood cell). It is a type of immunosuppressant. Also called Raptiva. (NCI Dictionary)

    Definition 2

    A humanized IgG1 monoclonal antibody directed against CD11a, the alpha subunit of human leukocyte-function-associated antigen type 1 (LFA-1), with immunosuppressant activity. Efalizumab binds to CD11a, which is expressed on all leukocytes, resulting in a reduction in the cell surface expression of CD11a. In addition, this agent inhibits the binding of LFA-1 to intercellular adhesion molecule-1 (ICAM-1), resulting in the inhibition of leukocyte adherence and the suppression of cell-mediated immunity. LFA-1 binding to ICAM-1 is involved in the activation of T lymphocytes, adhesion of T lymphocytes to endothelial cells, and migration of T lymphocytes to sites of inflammation. (NCI Thesaurus)




    YOU MAY ALSO LIKE

    A drug that is used to plan cancer treatment by measuring oxygen levels in tumor cells.
    Forming a single Ca2+-binding site in many calcium-binding proteins, the basic EF-Hand Domain consists of a conserved 12-residue loop region between two…
    A synthetic peptide derived from the protein ESW/FLI1 type 2 with potential use in cancer immunotherapy. EWS/FLI1 is a fusion protein frequently…
    A synthetic peptide derived from the protein ESW/FLI1 type 1 with potential use in cancer immunotherapy. EWS/FLI1 is a fusion protein frequently…
    A treatment being studied to improve brain function in certain brain disorders and in patients treated with chemotherapy for breast cancer. Sensors…
    A recording of electrical activity in the brain. It is made by placing electrodes on the scalp (the skin covering the top…

    © 1991-2023 The Titi Tudorancea Bulletin | Titi Tudorancea® is a Registered Trademark | Terms of use and privacy policy
    Contact